Plus500 Reaffirms FullYear Guidance After 11 Revenue Growth in Latest Quarter States Face Fiscal Strain as Welfare Spending Weighs on Revenue Growth Morgan Stanley G7 Unity Under Strain as Members Consider Dropping 2026 Communique Plans SafeHaven Currencies Gain as DeepSeek AI News Rattles Tech Stocks Page Industries Reports Strong Top Line Growth as Revenue from Operations and Sales Volume Increase BofA Upgrades Outlook for Philip Morris International with 9 Price Target Increase IQ Q1 2026 Earnings EPS Misses Estimates Stock Rises 66 XNCR Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Movement OVID Q1 2026 Earnings Narrower Loss and No Revenue Mark a Quiet Quarter for the Biotech RFIL Q1 2026 Earnings Strong EPS Beat of 96 Surprises Analysts Arbor Realty Trust ABR Q1 2026 Earnings Earnings Miss by Wide Margin as EPS Falls 40 Below Estimates REGCP Q1 2026 Earnings Preferred Dividend Coverage Beats Estimates Revenue Data Unavailable Ranpak Holdings PACK Posts 18 Gain Approaches Key Resistance Level NHPAP Holds Steady Near Resistance Preferred Shares Edge Higher AN2 Therapeutics ANTX Eases 21 Testing Key Support Near 440 Adobe Stock Edges Higher as Investors Eye Key Resistance Levels LivaNova LIVN Edges Higher as Stock Tests Key Resistance at 7752 Eicher Motors Rides Indias Premium Bike Boom But Valuations and EV Risks Loom FISI Q1 2026 Earnings Earnings Beat Drives EPS Above Expectations Amid Flat Revenue i80 Gold Corp IAUX Surges 658 as Gold Sector Optimism Drives Momentum ONE Gas Inc OGS Q1 2026 Earnings EPS Misses Estimates Yet Shares Edge Higher Tuya Q1 2026 Earnings EPS Falls Just Short of Estimates Stock Unchanged STTK Q1 2026 Earnings Narrower Loss Surprises as Biotech Advances Pipeline ENI SpA E Q1 2026 Earnings Earnings Miss Weighs on Shares as EPS Falls Short of Expectations ClearPoint Neuro Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Movement KG Q3 2024 Earnings Loss Reported Amid Limited Disclosure Stock Declines Verrica Pharmaceuticals VRCA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Sees Modest Stock Gain